Coherus Oncology (CHRS) Expected to Post Quarterly Earnings on Monday

Coherus Oncology (NASDAQ:CHRS) is projected to post its Q3 2026 results after the market closes on Monday, November 9th. Analysts expect the company to post earnings of ($0.22) per share and revenue of $15.90 million for the quarter. Parties may review the information on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Monday, November 9, 2026 at 5:00 PM ET.

Coherus Oncology (NASDAQ:CHRS) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.06. The firm had revenue of $14.31 million during the quarter, compared to analysts’ expectations of $14.41 million. Coherus Oncology had a negative return on equity of 222.75% and a negative net margin of 259.41%. On average, analysts expect Coherus Oncology to post ($0.88) EPS for the current fiscal year and ($0.83) EPS for the next fiscal year.

Coherus Oncology Stock Performance

NASDAQ:CHRS opened at $0.83 on Monday. The company has a market capitalization of $128.25 million, a PE ratio of -0.81 and a beta of 1.03. Coherus Oncology has a 52-week low of $0.81 and a 52-week high of $2.62. The stock’s 50 day moving average price is $1.20 and its 200 day moving average price is $1.53. The company has a quick ratio of 1.70, a current ratio of 1.77 and a debt-to-equity ratio of 0.61.

Key Headlines Impacting Coherus Oncology

Here are the key news stories impacting Coherus Oncology this week:

• Positive Sentiment: New data for tagmokitug reportedly support advancing the program into a broader study. The update could improve investor confidence in Coherus Oncology’s pipeline and provide a potential catalyst if expanded testing confirms the treatment’s benefit. Coherus Oncology stock: Tagmokitug data support broader study
• Positive Sentiment: HC Wainwright initiated coverage with a Buy rating. Its forecasts anticipate Coherus Oncology’s losses narrowing from an estimated $0.91 per share in fiscal 2026 to $0.63 in fiscal 2027, $0.48 in fiscal 2028 and $0.19 in fiscal 2029, before turning profitable at $0.19 per share in fiscal 2030. This projected improvement offers a longer-term bullish argument for the stock. HC Wainwright Initiates Coverage on Coherus Oncology
• Neutral Sentiment: HC Wainwright’s quarterly forecasts call for continued losses, including estimated EPS of negative $0.22 in Q3 2026 and negative $0.21 in Q4 2026, followed by losses ranging from $0.17 to $0.13 per share during 2027. The estimates provide a clearer outlook but do not imply near-term profitability.
• Negative Sentiment: HC Wainwright’s fiscal 2026 loss estimate of $0.91 per share is slightly worse than the broader consensus estimate of $0.87. Continued negative earnings could weigh on sentiment, particularly while CHRS remains well below its 50-day and 200-day moving averages and faces biotechnology-sector financing and execution risks.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Weiss Ratings raised Coherus Oncology from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, October 26th. HC Wainwright assumed coverage on shares of Coherus Oncology in a report on Thursday. They issued a “buy” rating on the stock. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $11.00.

Coherus Oncology Company Profile

Coherus Oncology, formerly known as Coherus BioSciences, is a commercial-stage biopharmaceutical company focused primarily on developing and commercializing medicines for cancer and other serious diseases. The company has built its business around biologic therapies, including biosimilars and innovative treatments intended to improve access to important medicines.

Its portfolio includes UDENYCA (pegfilgrastim-cbq), a long-acting treatment used to reduce the risk of infection associated with chemotherapy, and LOQTORZI (toripalimab-tpzi), an immuno-oncology therapy approved in the United States for certain patients with nasopharyngeal carcinoma.